The US Food and Drug Administration (FDA) has approved an investigational new drug application from Vegenics, a subsidiary of Circadian Technologies, to commence clinical trials of VGX-100 for the treatment cancer patients with solid tumours.

VGX-100 is a human antibody that acts against the human VEGF-C protein.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

In animal models, VGX-100 combined with Avastin and chemotherapy has been shown to reduce tumour growth and tumour spread, and improve tumour inhibition.

The Phase I study will investigate VGX-100 in patients with a variety of late-stage cancers.

Circadian Technologies CEO Robert Klupacs said the company expects to start clinical trials before the end of 2011, with results becoming available in the second half of 2012.

The company is also developing VGX-100 for other cancer indications, as well as an agent to treat front-of the-eye diseases.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact